ASND Ascendis Pharma A/S
- 126.005
- +1.185+0.95%
Ascendis Pharma A/S News
Ascendis Pharma (ASND) Receives a Hold From TD Cowen
US Equity Markets Close Higher Tuesday as Producer Prices Rise
US equity markets ended higher Tuesday as the producer price index increased more than expected. * The US Producer Price Index rose 0.5% in April following a downwardly revised 0.1% decrease in March,
Sector Update: Health Care Stocks Rise in Late Afternoon Trading
Health care stocks were higher late Tuesday afternoon, with the NYSE Health Care Index adding 0.5% and the Health Care Select Sector SPDR Fund (XLV) up 0.5%. The iShares Biotechnology ETF (IBB) rose 0
FDA Delays Ascendis Pharma's Drug Review
Ascendis Pharma A/S (ASND) has released an update.
Sector Update: Health Care
Health care stocks were higher late Tuesday afternoon, with the NYSE Health Care Index adding 0.5% and the Health Care Select Sector SPDR Fund (XLV) up 0.3%. The iShares Biotechnology ETF (IBB) rose 0
Ascendis Pharma Says FDA Has Delayed TransCon PTH Review
Ascendis Pharma Says FDA Extending Review Period for NDA
By Ben Glickman Ascendis Pharma said regulators had pushed back the target action date for reviewing its hypoparathyroidism treatment after the company submitted additional information. The Danish b
UPDATE 1-FDA Extends Review of Ascendis Pharma's Hormone Disorder Therapy
Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon PTH for Adults With Hypoparathyroidism
- Prescription Drug User Fee Act (PDUFA) goal date extended by three months for further review of submission to August 14, 2024 COPENHAGEN, Denmark, May 14, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND)
Ascendis Pharma Announces 2-Year Results From A Post-hoc Analysis Of Their Phase 3 Pathway Trial Demonstrating Sustained Improvements In Renal Function In Adults With Chronic Hypoparathyroidism Treated With TransCon PTH
Ascendis Pharma A/S (NASDAQ:ASND) today announced 2-year results from a post-hoc analysis of the Company's Phase 3 PaTHway Trial demonstrating significant and sustained improvements in renal function
Ascendis Pharma A/S Clinical And Quality-Of-Life Data For TransCon PTH-Treated Adults With Chronic Hypoparathyroidism To Be Presented At ECE 2024
Ascendis Pharma A/S (NASDAQ:ASND) today announced that new TransCon PTH (palopegteriparatide) data supporting clinical and quality-of-life benefits in adult patients with chronic hypoparathyroidism wi
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
European equities traded in the US as American depositary receipts started the week off on a positive note, rising 0.42% to 1,380.39 on the S&P Europe Select ADR Index. From continental Europe, the ga
Ascendis Pharma Is Maintained at Overweight by JP Morgan
Ascendis Pharma Is Maintained at Overweight by JP Morgan
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower
European equities traded in the US as American depositary receipts were trending modestly higher Friday morning, rising 0.42% to 1,371.48 on the S&P Europe Select ADR Index. Despite the gain, the inde
Ascendis Pharma Price Target Maintained With a $173.00/Share by Cantor Fitzgerald
Ascendis Pharma Price Target Maintained With a $173.00/Share by Cantor Fitzgerald
Cantor Fitzgerald Corp.: Reiterates Ascendis Pharma (ASND.US) rating and adjusted from an increase to an increase in holdings rating, with a target price of $173.00.
Cantor Fitzgerald Corp.: Reiterates Ascendis Pharma (ASND.US) rating and adjusted from an increase to an increase in holdings rating, with a target price of $173.00.
Ascendis Pharma Q1 Net Loss Widens, Revenue Rises
Ascendis Pharma (ASND) reported a Q1 net loss late Thursday of 2.30 euros ($2.47) per diluted share, compared with a loss of 1.98 euros a year earlier. Analysts polled by Capital IQ expected a per-sha
Ascendis Pharma Q1 Sales €95.894M Beat €79.492M Estimate
Ascendis Pharma Q1 Sales €95.894M Beat €79.492M Estimate
Ascendis Pharma Reports Q1 Results
Ascendis Pharma: As of March 31Had Cash, Cash Equivalents, Marketable Securities Totaling EUR320 >ASND
Ascendis Pharma: As of March 31Had Cash, Cash Equivalents, Marketable Securities Totaling EUR320 >ASND
Analysis
Price Target
No Data
